(Circulation. 1996;94:1746-1751.)
© 1996 American Heart Association, Inc.
Articles |
Thrombogenic Properties of Murine Anti-Cardiolipin Antibodies Induced by ß2 Glycoprotein 1 and Human Immunoglobulin G Antiphospholipid Antibodies
the Antiphospholipid Standardization Laboratory (S.S.P.) and Department of Internal Medicine (E.N.H.), Morehouse School of Medicine, Atlanta, Ga, and the Department of Medicine, Division of Rheumatology (X.W.L.), Department of Physiology (G.A.), and Department of Surgery (J.H.B.), University of Louisville (Ky).
Correspondence to Silvia S. Pierangeli, PhD, Lab Director, Antiphospholipid Standardization Laboratory, Department of Microbiology and Immunology, Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310.
Background Recurrent arterial thrombosis and venous thrombosis are frequent complications of the antiphospholipid syndrome (APS). Patients produce anti-cardiolipin antibodies, but the role of these antibodies in thrombus formation is uncertain. This study used a unique CD-1 mouse model of thrombosis to determine whether anti-cardiolipin and anti-ß2 glycoprotein 1 (ß2GP1) antibodies induced immunologically in these animals are thrombogenic.
Methods and Results The CD-1 mouse model enables measurement of the kinetics of a thrombus induced in the femoral vein of the animal. Animals are first anesthetized, then one femoral vein is exposed and subjected to a standardized, nonpenetrating "pinch" injury that induces a thrombus. The vein is transilluminated, and the growing thrombus is visualized on a television screen. The rate of formation and disappearance of the thrombus as well as its area can be measured by a computer attached to the television. Three groups of CD-1 mice (each group comprising seven animals) were studied. Group 1 mice were actively immunized with ß2GP1, resulting in production of anti-ß2GP1 and anti-cardiolipin antibodies. Group 2 mice were actively immunized with human immunoglobulin G (IgG) anti-cardiolipin antibodies and produced anti-human IgG as well as anti-cardiolipin antibodies (the latter by an idiotype–anti-idiotype reaction). These animals did not produce anti-ß2GP1 antibodies. Group 3 mice were immunized with human serum albumin (HSA) and produced anti-HSA but not anti-cardiolipin antibodies. The kinetics of thrombus formation induced in the femoral veins of the experimental mice were compared. Results showed that the mean thrombus area as well as mean time during which thrombi persisted were significantly greater in group 1 and group 2 mice compared with group 3. There was no statistical difference between group 1 or group 2.
Conclusions Demonstration of a thrombogenic effect of murine anti-cardiolipin antibodies suggests that these antibodies may be pathogenic in humans with APS.
Key Words: antibodies • anticoagulants • thrombosis • antigens • apolipoproteins
This article has been cited by other articles:
 |
|
 |
|
  C. Perricone, C. De Carolis, R. Giacomelli, G. Zaccari, P. Cipriani, E. Bizzi, and R. Perricone High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis Rheumatology, October 1, 2007; 46(10): 1574 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Shoenfeld and M Blank Autoantibodies associated with reproductive failure Lupus, September 1, 2004; 13(9): 643 - 648. [Abstract] [PDF]
|
|
|
|
|
|
A E Gharavi, M Vega-Ostertag, R G Espinola, X Liu, L Cole, N T Cox, P Romagnoli, K Labat, and S S Pierangeli Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies Lupus, January 1, 2004; 13(1): 17 - 23. [Abstract] [PDF]
|
|
|
|
|
|
A E Gharavi, W Wilson, and S Pierangeli The molecular basis of antiphospholipid syndrome Lupus, August 1, 2003; 12(8): 579 - 583. [Abstract] [PDF]
|
|
|
|
|
|
S Haj-Yahja, Y Sherer, M Blank, H Kaetsu, A Smolinsky, and Y Shoenfeld Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model Lupus, May 1, 2003; 12(5): 364 - 369. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Jankowski, I. Vreys, C. Wittevrongel, D. Boon, J. Vermylen, Marc. F. Hoylaerts, and J. Arnout Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster Blood, January 1, 2003; 101(1): 157 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fischer, H. Collins, M. Taniguchi, S. H. E. Kaufmann, and U. E. Schaible IL-4 and T Cells Are Required for the Generation of IgG1 Isotype Antibodies Against Cardiolipin J. Immunol., March 15, 2002; 168(6): 2689 - 2694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Levine and B. S. Jacobs 2001: A Prospective, Seasonal Odyssey Into Antiphospholipid Protein Antibodies Stroke, August 1, 2001; 32(8): 1699 - 1700. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Pierangeli, R. G. Espinola, X. Liu, and E. N. Harris Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin Circ. Res., February 2, 2001; 88(2): 245 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Isenberg, D Katz, P Maddison, R Watts, L Tucker, and A Cooke Induction of anti-DNA antibodies: commentary on article by Satake et al Lupus, January 1, 2001; 10(1): 63 - 65. [PDF]
|
|
|
|
|
|
R. Caliz, T. Atsumi, E. Kondeatis, O. Amengual, M. A. Khamashta, R. W. Vaughan, J. S. Lanchbury, and G. R. V. Hughes HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients Rheumatology, January 1, 2001; 40(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Shoenfeld Eppur si muove (Galileo Galilei 1564-1642): the idiotypic dysregulation of autoantibodies as part of the etiology of SLE Lupus, September 1, 2000; 9(7): 481 - 483. [PDF]
|
|
|
|
 |
|
 F.B. KARASSA, J.P.A. IOANNIDIS, G. TOULOUMI, K.A. BOKI, and H.M. MOUTSOPOULOS Risk factors for central nervous system involvement in systemic lupus erythematosus QJM, March 1, 2000; 93(3): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blank, A. Waisman, E. Mozes, T. Koike, and Y. Shoenfeld Characteristics and pathogenic role of anti-{beta}2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome Int. Immunol., December 1, 1999; 11(12): 1917 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Afek, Y Shoenfeld, R Manor, I Goldberg, L Ziporen, J George, S Polak-Charcon, M C Amigo, R Garcia-Torres, R Segal, et al. Increased endothelial cell expression of a3{beta}1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome Lupus, September 1, 1999; 8(7): 502 - 507. [Abstract] [PDF]
|
|
|
|
|
|
A. E. Gharavi, S. S. Pierangeli, M. Colden-Stanfield, X. W. Liu, R. G. Espinola, and E. N. Harris GDKV-Induced Antiphospholipid Antibodies Enhance Thrombosis and Activate Endothelial Cells In Vivo and In Vitro J. Immunol., September 1, 1999; 163(5): 2922 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E E Gharavi, H Chaimovich, E Cucurull, C M Celli, H Tang, W A Wilson, and A E Gharavi Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides Lupus, July 1, 1999; 8(6): 449 - 455. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Blank, Y. Shoenfeld, S. Cabilly, Y. Heldman, M. Fridkin, and E. Katchalski-Katzir Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides PNAS, April 27, 1999; 96(9): 5164 - 5168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Pierangeli, M. Colden-Stanfield, X. Liu, J. H. Barker, G. L. Anderson, and E. N. Harris Antiphospholipid Antibodies From Antiphospholipid Syndrome Patients Activate Endothelial Cells In Vitro and In Vivo Circulation, April 20, 1999; 99(15): 1997 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tanne, L. D'Olhaberriague, L. R. Schultz, L. Salowich-Palm, K. L. Sawaya, and S. R. Levine Anticardiolipin antibodies and their associations with cerebrovascular risk factors Neurology, April 1, 1999; 52(7): 1368 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Gharavi, S S Pierangeli, E E Gharavi, T Hua, X W Liu, J H Barker, G H Anderson, and E N Harris Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to {beta}2 glycoprotein 1 ({beta}2GP1) alone Lupus, June 1, 1998; 7(5): 341 - 346. [Abstract] [PDF]
|
|
|
|
|
|
J. George, M. Blank, Y. Levy, P. Meroni, M. Damianovich, A. Tincani, and Y. Shoenfeld Differential Effects of Anti–ß2-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome Circulation, March 10, 1998; 97(9): 900 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Edwards, S. Pierangeli, X. Liu, J. H. Barker, G. Anderson, and E. N. Harris Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice Circulation, December 16, 1997; 96(12): 4380 - 4384. [Abstract] [Full Text]
|
|
|
|
|
|
J. George, A. Afek, B. Gilburd, Y. Levy, M. Blank, J. Kopolovic, D. Harats, and Y. Shoenfeld Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies Lupus, January 1, 1997; 6(9): 717 - 729. [Abstract] [PDF]
|
|